Mustang Bio Expands CAR-T Therapy into Autoimmune Diseases

Introduction

Mustang Bio, Inc. (Nasdaq: MBIO) is a clinical-stage biopharmaceutical company headquartered in Waltham, Massachusetts. Founded by Fortress Biotech, the company focuses on translating advancements in cell and gene therapies into potential treatments for cancers and rare genetic diseases. Mustang Bio develops CAR-T therapies and oncolytic virus platforms in collaboration with various medical institutions.

Corporate Structure

According to its LinkedIn profile, Mustang Bio employs between 51 and 200 people. The company’s common stock trades on the Nasdaq under the ticker symbol MBIO. Mustang Bio holds licensing or ownership interests in cell-therapy technologies and partners with leading research centers, including Fred Hutchinson Cancer Center, City of Hope, and Nationwide Children’s Hospital, to advance its clinical programs.

CAR-T therapy by Anton Darius

Pipeline and Developments

Mustang Bio’s pipeline comprises four principal programs:

• MB-106 (CD20-targeted CAR-T): A third-generation CAR-T therapy currently undergoing a physician-sponsored IND study for B-cell non-Hodgkin lymphoma (NHL).
• MB-101 (IL-13Rα2 CAR-T): Aimed at a receptor present in over 75% of glioblastoma patients; early clinical response data has emerged from a City of Hope physician IND trial.
• C134 (oncolytic HSV): A herpes simplex virus designed to selectively replicate in tumor cells. It was licensed in February 2019 for the treatment of glioblastoma multiforme.
• MB-109 (combination therapy): A regimen combining MB-101 and C134, targeting the enhancement of CAR-T cell infiltration in tumors. An industry-sponsored trial is planned for the second half of 2025 in recurrent glioblastoma and high-grade astrocytomas.

Key announcements include:

• March 28, 2024: Mustang Bio announced plans to initiate a Phase 1 investigator-sponsored trial of MB-106 for treating autoimmune diseases, expected to begin in the fourth quarter of 2024.
• February 27, 2025: The company announced the termination of its lease for the Worcester manufacturing facility, selling fixed assets to AbbVie Bioresearch Center, Inc. for $1.0 million. The lease termination is projected to save approximately $2.0 million in cash expenses over 24 months, and the corporate headquarters has been relocated to 95 Sawyer Road, Waltham, MA.

Financial and Strategic Analysis

As of July 2, 2025, Mustang Bio shares closed at $1.44 on the Nasdaq, with a daily trading volume of 253,803 shares, representing a decrease of 29.76% from the prior trading session. Strategic investor positions were reported in Schedule 13G/A filings:

• Armistice Capital, LLC and Steven Boyd: Beneficially own 4.99% of Mustang Bio’s common stock (filed May 15, 2025).
• Intracoastal Capital LLC, Mitchell P. Kopin, and Daniel B. Asher: Hold 8.8% of the common shares (filed May 9, 2025).

The company filed its quarterly report (Form 10-Q) on May 14, 2025. While detailed financial figures were not disclosed in public summaries, the divestment of its manufacturing facility and the focus on investigator-sponsored trials align with efforts to reduce operating expenses and support development activities. The expansion into autoimmune indications, in conjunction with ongoing oncology programs, broadens Mustang Bio’s strategic risk profile.

Market Position and Industry Context

Mustang Bio operates within the cell-therapy and gene-therapy sectors, where regulatory approval processes are complex, and clinical trial outcomes can significantly affect company valuations. By leveraging partnerships with academic research institutions, Mustang Bio is positioned within a competitive landscape of biotechnology firms focused on developing next-generation immunotherapies. With a workforce of under 200 employees, Mustang Bio relies on collaborations and contract manufacturing to support its clinical initiatives.

TL;DR

• On February 27, 2025, Mustang Bio sold its Worcester manufacturing facility and entered into a $1 million asset sale to AbbVie, targeting $2 million in savings from lease-related expenses over 24 months.
• The company has commenced the expansion of MB-106 CAR-T therapy into autoimmune diseases under a Phase 1 investigator-sponsored trial expected to begin in Q4 2024.
• A combination trial of MB-101 and oncolytic virus C134 (MB-109) is planned for the second half of 2025 in recurrent glioblastoma.
• As of July 2, 2025, MBIO shares closed at $1.44 on the Nasdaq, down 29.76% intraday, with significant stakes held by Armistice Capital (4.99%) and Intracoastal Capital (8.8%).